Greenwich Lifesciences Inc GLSI

$19.79 -0.79 (-3.84%)

Valuation

Market cap
274,479,000
Revenue TTM
$0
Net income TTM
$-19,360,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
230,600
Avg volume
163,212
Day's range
$19.39 – $20.97
Shares out
14,678,000
Stochastic %K
84%
Beta
1.57
Analysts
Moderate Buy
Price target
$57.00

Price

Company profile

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I...

Show more

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.

Industry
Biotechnology
Sector
Healthcare
Phone
832-819-3232
Website
https://greenwichlifesciences.com
Address
Building 14, 3992 Bluebonnet Dr., Stafford, United States

Latest news

Stocktwits

Vextra Nov 19, 9:15 PM
Look at ticker FGI spiking now. crazy! If you want to be early for once look at FGI 🚀 FGI is just starting lets hope it pulls a OMH 2,000% type of run!! FGI on watch from $ASPC $GLSI $RDW $>
1 replies
GridironGainz Nov 19, 8:46 PM 0 replies
HboFam Nov 19, 7:19 PM
$GLSI reminds me of snehel and his family cashing and their puny rebuys
2 replies
Waterwing Nov 19, 6:50 PM
$GLSI C-GPT notice... What the first of two SABCS presentations actually cover... I checked the official conference program and identified both presentations. P1-15-24: Preliminary efficacy and safety results Open-label, non-HLA-A*02 patients receiving GLSI-100 in FLAMINGO-01. December 9 · 12:30–2:00 p.m. Central This is the more important poster for investors because it specifically addresses preliminary efficacy and safety. Official SABCS Poster Session 1⁠ 2: P2-2-15: Phase III study design Overview of the GLSI-100 FLAMINGO-01 Phase 3 study. December 9 · 5:00–6:30 p.m. Central This is a study-design presentation, not a second announcement of efficacy results. Official SABCS Poster Session 2⁠
0 replies
RiderInTheSky Nov 19, 5:31 PM
$GLSI When I opened my position in GLSI I was also considering SLS & VKTX. I ultimately decided on GLSI favoring Patels leadership qualities & shareholder friendly plus a lot of skin in the game. I hv been burned 🔥 before on management. I am confident with my decision on Patel & his style. Hv added more when it dipped to low $13’s & glad I did !
0 replies
Rolltide2020 Nov 19, 3:56 PM
$GLSI The cash balance at the end of Q4 2025 was around $6.1 million. Almost 1 year later and we are basically at the same level except now we have FDA/EMA trial approval for all HLA types, City of Hope, Royal Mardsden, FDA approval on 1st manufacturing lot, Fast Track approval, and over 1 year of open label data likely still pointing to 70 - 80% reduction. SLS gave us a nice science confirmation this week. Obviously we are going to need more cash (either through ATM or partnership or small raise) somewhere along the way, but for anyone to think money will be the reason we don't make it to finish line seems crazy and anyone who thinks Snehal will do any major dilulitive financing hasn't done their homework.
1 replies
buffetthemuffet Nov 19, 3:50 PM
$GLSI Back to 6 or 7 range
2 replies
LIGator Nov 19, 3:14 PM
$GLSI Another emphatic difference between how GLSI & SLS treats the shareholders. SLS raised $150M at almost $5 per share below yesterday’s closing price. That is telling Wall Street that they would rather have $150M cash instead of an extra $1 billion in market cap. With insiders owning the majority of GLSI that kind of toxic financing would never happen.
2 replies